Page last updated: 2024-12-10
uredofos
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
uredofos: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3033943 |
| CHEMBL ID | 2105590 |
| SCHEMBL ID | 1815546 |
| MeSH ID | M0059641 |
Synonyms (31)
| Synonym |
|---|
| phosphoramidic acid, [[[2-[[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-, diethyl ester |
| uredofos |
| o,o-diethyl n-((2-(3-(4-tolylsulfonyl)ureido)phenyl)thiocarbamoyl)amidophosphat |
| uredofosum [inn-latin] |
| phosphoramidic acid, (((2-(((((4-methylphenyl)sulfonyl)amino)carbonyl)amino)phenyl)amino)thioxomethyl)-, diethyl ester |
| 1-(3-p-tolylsulfonylureido)-2-(3-diethylphosphonothioureido)benzene |
| sansalid |
| rh 32565 |
| phosphoroamidic acid, (((2-(((((4-methylphenyl)sulfonyl)amino)carbonyl)amino)phenyl)amino)thioxomethyl)-, diethyl ester |
| rh-32,565 |
| ureidofos |
| diethyl (thio(o-(3-(p-tolylsulfonyl)ureido)phenyl)carbamoyl)phosphoramidate |
| D06267 |
| uredofos (usan/inn) |
| 52406-01-6 |
| 1-[2-(diethoxyphosphorylcarbamothioylamino)phenyl]-3-(4-methylphenyl)sulfonylurea |
| CHEMBL2105590 |
| rh-32565 |
| p8w25x9b3k , |
| rh-565 |
| uredofos [usan:inn:ban] |
| unii-p8w25x9b3k |
| uredofosum |
| uredofos [mi] |
| uredofos [inn] |
| uredofos [usan] |
| SCHEMBL1815546 |
| DTXSID0073534 |
| diethyl ((2-(3-tosylureido)phenyl)carbamothioyl)phosphoramidate |
| Q27286383 |
| AKOS040747567 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||